Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
暂无分享,去创建一个
Ozy Sjahputera | Huidong Shi | Charles W Caldwell | Juyuan Guo | Farahnaz Rahmatpanah | O. Sjahputera | Huidong Shi | K. Taylor | C. Caldwell | F. Rahmatpanah | Juyuan Guo | M. Al-Kuhlani | J. Wooldridge | D. Duff | Rebecca Chitima-Matsiga | Melinda W. Andreski | Rebecca Chitima-Matsiga | Kristen H Taylor | Deiter J Duff | Mufadhal Al-Kuhlani | Melinda Andreski | James E Wooldridge
[1] A. Saci,et al. RhoA GTPase regulates B cell receptor signaling. , 2005, Molecules and Cells.
[2] M. Caligiuri,et al. Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.
[3] L. Medeiros,et al. Real-Time RT-PCR Assay for Quantifying Cyclin D1 mRNA in B-Cell Non-Hodgkin's Lymphomas , 2002, Modern Pathology.
[4] Chen Li,et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling , 2004, Nature Neuroscience.
[5] Xiangyin Kong,et al. Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. , 2005, Human pathology.
[6] S. Thorgeirsson,et al. DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma. , 2003, International journal of oncology.
[7] M Dickson,et al. Comparative DNA sequence analysis of mouse and human protocadherin gene clusters. , 2001, Genome research.
[8] R. Momparler,et al. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells , 2001, Cancer Chemotherapy and Pharmacology.
[9] J. Herman,et al. A gene hypermethylation profile of human cancer. , 2001, Cancer research.
[10] S. Thorgeirsson,et al. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas , 2004, Oncogene.
[11] T. McDonnell,et al. Characterization of 4 mantle cell lymphoma cell lines. , 2003, Archives of pathology & laboratory medicine.
[12] I. Ng,et al. Genetic and Epigenetic Alterations of DLC1 Gene in Hepatocellular Carcinoma , 2003 .
[13] J. McNeal,et al. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. , 2001, Cancer research.
[14] Tim Hui-Ming Huang,et al. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. , 2002, Cancer research.
[15] S. Thorgeirsson,et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. , 1998, Cancer research.
[16] I. Ng,et al. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. , 2000, Cancer research.
[17] Jung Weon Lee,et al. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells , 2003, Oncogene.
[18] H. Cross,et al. Epigenetic regulation of Vitamin D hydroxylase expression and activity in normal and malignant human prostate cells , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[19] Tim Hui-Ming Huang,et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] J. Welsh. Vitamin D and breast cancer: insights from animal models. , 2004, The American journal of clinical nutrition.
[21] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[22] Igor Jurisica,et al. CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome , 2005, Nucleic acids research.
[23] Yingye Zheng,et al. DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies , 2004, Clinical Cancer Research.
[24] D. Longo,et al. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. , 1990, Journal of the National Cancer Institute.
[25] Tim Hui-Ming Huang,et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. , 2003, Cancer research.
[26] P. Laird,et al. MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.
[27] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[28] S. Pileri,et al. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. , 2004, Haematologica.
[29] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[30] Tony Pawson,et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer , 2004, Nature Genetics.
[31] A. Bradley,et al. Molecular mechanisms governing Pcdh-gamma gene expression: evidence for a multiple promoter and cis-alternative splicing model. , 2002, Genes & development.
[32] Hirokazu Nagai,et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. , 2002, Blood.
[33] M. Durkin,et al. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. , 2003, Cancer genetics and cytogenetics.
[34] M. Esteller. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. , 2003, Clinical immunology.
[35] C. M. Chen,et al. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. , 2001, Cancer research.
[36] Huidong Shi,et al. The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin's lymphomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] Huidong Shi,et al. Differential DNA methylation of gene promoters in small B-cell lymphomas. , 2005, American journal of clinical pathology.
[38] Ryuzo Ohno,et al. Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy. , 2005, Cancer research.
[39] E. Epner,et al. Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. , 2004, Blood.
[40] I. Ng,et al. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. , 2003, Cancer research.
[41] A. Harris,et al. Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate Disease , 2005, Clinical Cancer Research.
[42] R. Warnke,et al. CyclinD1/CyclinD3 ratio by real-time PCR improves specificity for the diagnosis of mantle cell lymphoma. , 2004, The Journal of molecular diagnostics : JMD.
[43] P. Circosta,et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. , 1999, Leukemia research.
[44] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.